Beam SVP sells shares to cover RSU taxes

Beam Therapeutics SVP Finance Bethany J. Cavanagh reported an automatic sale of common stock mainly to cover taxes on vesting equity awards.

Rhea-AI Filing Summary

Beam Therapeutics SVP Finance Bethany J. Cavanagh reported an automatic sale of common stock mainly to cover taxes on vesting equity awards. On April 1, 2026, 3,242 shares were sold in an open-market transaction at $24.58 per share. These shares were sold to satisfy tax withholding obligations tied to restricted stock units granted under the company’s 2019 Equity Incentive Plan that vested on multiple March 31 dates from 2022 through 2025. Following the sale, Cavanagh directly holds 51,171 Beam Therapeutics shares. The filing notes the transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 9, 2024, indicating the timing was set in advance rather than chosen opportunistically.

Insider Trade Summary 10b5-1

Net Seller: 3,242 shares

Net Sell 1 txn

Insider Cavanagh Bethany J

Role SVP, Finance and Treasurer

Sold 3,242 shs ($80K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,242	$24.58	$80K

Holdings After Transaction: Common Stock — 51,171 shares (Direct)

Footnotes (1)

1. F1. These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. 2019 Equity Incentive Plan on each of March 31, 2022, March 31, 2023, March 31, 2024 and March 31, 2025. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 9, 2024.

Key Figures

Shares sold: 3,242 shares Sale price per share: $24.58/share Shares held after transaction: 51,171 shares +2 more

5 metrics

Shares sold 3,242 shares Open-market sale on April 1, 2026 to cover tax withholding

Sale price per share $24.58/share Price for Beam Therapeutics common stock in the reported sale

Shares held after transaction 51,171 shares Direct Beam Therapeutics holdings by Bethany Cavanagh after the sale

RSU vesting dates March 31, 2022–2025 Vesting dates of RSUs that created tax withholding obligations

10b5-1 plan adoption date August 9, 2024 Date Cavanagh adopted the Rule 10b5-1 trading plan

Key Terms

restricted stock units, tax withholding obligations, 2019 Equity Incentive Plan, Rule 10b5-1 trading plan

4 terms

restricted stock units financial

"upon the vesting of certain restricted stock units granted to the Reporting Person"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations"

2019 Equity Incentive Plan financial

"granted to the Reporting Person under the Beam Therapeutics Inc. 2019 Equity Incentive Plan"

Rule 10b5-1 trading plan regulatory

"The sales were effected pursuant to a Rule 10b5-1 trading plan adopted"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Beam Therapeutics (BEAM) report for Bethany Cavanagh?

Beam Therapeutics reported that SVP Finance Bethany J. Cavanagh sold 3,242 shares of common stock. The shares were sold in an automatic, non-discretionary transaction mainly to cover tax withholding obligations arising from vesting restricted stock units granted under the 2019 Equity Incentive Plan.

At what price were Bethany Cavanagh’s Beam Therapeutics (BEAM) shares sold?

The 3,242 Beam Therapeutics shares were sold at an average price of $24.58 per share. This open-market transaction was executed automatically under a Rule 10b5-1 trading plan, as part of satisfying tax withholding obligations from vesting restricted stock units.

How many Beam Therapeutics (BEAM) shares does Bethany Cavanagh hold after the transaction?

After the tax-related sale, Bethany Cavanagh directly holds 51,171 shares of Beam Therapeutics common stock. This remaining position reflects her ongoing equity stake with the company following the automatic sale of 3,242 shares executed on April 1, 2026.

Why were Bethany Cavanagh’s Beam Therapeutics (BEAM) shares sold automatically?

The shares were automatically sold to cover tax withholding obligations from vesting restricted stock units granted in 2022, 2023, 2024, and 2025. Such tax-related sales are common for equity awards and do not necessarily reflect a discretionary change in the insider’s investment view.

Was Bethany Cavanagh’s Beam Therapeutics (BEAM) share sale under a Rule 10b5-1 plan?

Yes. The filing states the sale was executed under a Rule 10b5-1 trading plan adopted on August 9, 2024. These pre-arranged plans schedule trades in advance, which can reduce the significance of the transaction’s timing as a signal of insider sentiment.

What equity awards triggered the tax-related sale at Beam Therapeutics (BEAM)?

The tax-related sale was triggered by vesting of restricted stock units granted to Bethany Cavanagh under the Beam Therapeutics 2019 Equity Incentive Plan. Units vested on March 31 of 2022, 2023, 2024, and 2025, creating tax withholding obligations satisfied via the share sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/06/2026 - 05:39 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cavanagh Bethany J

(Last) (First) (Middle)

C/O BEAM THERAPEUTICS INC.,

238 MAIN STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Beam Therapeutics Inc. [ BEAM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Finance and Treasurer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/01/2026		S(1)		3,242	D	$24.58	51,171	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. 2019 Equity Incentive Plan on each of March 31, 2022, March 31, 2023, March 31, 2024 and March 31, 2025. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 9, 2024.

	By: /s/ Christine Bellon, Attorney-in-fact	04/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)